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ABSTRACT
Objective: Dasatinib (DST) is a Biopharmaceutics Classification System Class II drug having very low solubility and high permeability. Low aqueous 
solubility and poor dissolution of DST lead to poor bioavailability, Thus, limited aqueous solubility is the bottleneck for the therapeutic outcome of 
DST. Animal data suggest that the absolute bioavailability of DST is about 14–34% due to an extensive first-pass effect. To overcome hepatic first-pass 
metabolism and to enhance oral bioavailability, lipid-based drug delivery systems such as solid lipid nanoparticles (SLNs) can be used.
Methods: SLNs are submicron colloidal carriers having a size range of 50–1000 nm. These are prepared with physiological lipid and dispersed 
in water or aqueous surfactant solution. DST can be conveniently loaded into SLNs to improve the oral bioavailability by exploiting the intestinal 
lymphatic transport. An optimal system was evaluated for bioavailability study in rats compared with that of DST suspension (SUS).
Results: An in vitro cytotoxicity study was done by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay method through ATCC cell 
lines; the percent inhibition was more in SLN when compared with SUS. The pharmacokinetics of DST-SLNs after oral administration in male Wistar 
rats was studied. The bioavailability of DST was increased by 2.28 fold when compared with that of a DST SUS.
Conclusion: The results are indicative of SLNs as suitable lipid-based carrier system for improving the oral bioavailability of DST.
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INTRODUCTION
The drugs with poor oral bioavailability are unable to reach the minimum 
effective concentration to exhibit therapeutic action. Some of the 
reasons for poor bioavailability include poor solubility, inappropriate 
partition coefficient as it influences the permeation of drug through 
lipid membrane, first-pass metabolism, P-glycoprotein mediated efflux, 
and degradation of drug in the gastrointestinal (GI) tract due to pH of 
the stomach or enzymatic degradation or by chemical [1].
Solid lipid nanoparticles (SLNs) are sub-micron colloidal carriers having a 
size range of 50–1000 nm. These are prepared with physiological lipid and 
dispersed in water or aqueous surfactant solution. SLNs were developed 
in the past decade as an alternative system to the existing traditional 
carriers, i.e., emulsions, liposomes, and polymeric nanoparticles [2,3]. 
These are related to emulsions, where the liquid lipid oil is substituted 
by a solid lipid. SLNs offer unique properties such as small size, large 
surface area, and high drug loading and are attractive for their potential 
to improve the performance of active pharmaceutical ingredients. The 
advantages of SLNs include drug targeting, biocompatibility, nontoxicity, 
drug release modulation, and small-scale production [4].
SLNs are also useful for the improvement of bioavailability of poorly 
water-soluble drugs, such as cyclosporine A [5], and to prolong the 
release of lipophilic drugs, such as camptothecin [6]. The mechanism 
proposed for enhancement of bioavailability of poorly water-soluble 
drugs by use of oral lipids includes promotion of lymphatic transport, 
which delivers drug directly to the systemic circulation while avoiding 
hepatic first-pass metabolism and by increasing GI membrane 
permeability [7,8]. It is known that drug delivery through SLNs 
improved the pharmacokinetic (PK) behavior. SLNs of dasatinib (DST) 
were not yet reported till now; hence, there is a need to improve the 
solubility and bioavailability through this delivery system.
MATERIALS
DST was obtained as gift sample from Aurobindo labs, Hyderabad. 
ATCC-Leukemia Cell Line Panel was obtained from Sigma-Aldrich, USA. 
Culture media contains Dulbecco’s Modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin from Sigma-Aldrich, USA. Male Wistar rats were obtained 
from M/s. Sri Venketeswara Enterprises, Bangalore.
METHODS
In vitro cytotoxicity studies
Leukemia Cell Line Panel (ATCC® TCP-1010™) cells are used for the 
cytotoxicity of Dasatinib (DS)-SLNs. ATCC is a perpetual cell line 
consisting of human leukemia cells, derived from the genomic mutations 
in one or more of the following genes: CDKN2A, KDM6A, TP53, NRAS, 
NOTCH1, PTEN, FBXW7, FLT3, KRAS, MLH1, and PIK3R1. ATCC was 
cultured in DMEM supplemented with 10% FBS and 1% penicillin-
streptomycin at 37°C in a 5% CO2 incubator. This cell line has been well 
characterized for its relevance to the toxicity models in human.
Cell culture and treatment
Cells were seeded at 2, 50, 000 cells/flask in a total volume of 10 mL. 
When confluent, cells were trypsinized and seeded in 96 well plates at 
the rate of 1.0×104 cells/0.1 mL. All the cell cultures were maintained 
in a 5% CO2 incubator at 37°C. The control and SLNs were prepared as 
dispersions in different concentrations (10–100 µg/mL) in phosphate-
buffered saline as a solvent with <1% polyethylene glycol as a stabilizer 
and used for different assays.
Cell viability assay
The effect of DST-SLNs on the cellular proliferation and viability 
was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay method. The procedure for this assay 
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is as follows: Briefly, the cells were seeded in 96 well plates and to it, SLN 
and control suspension (SUS) (100 µL, in the triplicate) in media were 
added. The microtiter plates were then incubated at 37°C for 48 h in 5% 
CO2 incubator, and 20 µL of MTT (5 mg/mL) was added to each well. The 
plate was again incubated for 2 h, and dimethyl sulfoxide (80 µL) was 
added to each well and was wrapped in aluminum foil to prevent the 
oxidation of the dye. The plate was placed on a rotary shaker for 2 h for 
thorough mixing. The absorbance was recorded on the enzyme-linked 
immunosorbent assay reader at 321 nm. The absorbance of the test was 
compared with that of solvent control to get the cell viability [9,10].
In vivo bioavailability study
Male Wistar rats were obtained from M/s. Sri Venketeswara 
Enterprises, Bangalore. The animals were quarantined in the animal 
house. Rats had free access to food and water ad libitum. The study 
protocol was approved by the Institutional Animal Ethics Committee 
(P.COL/15/2018 IAEC.VMCP). Twelve male Wistar rats weighing 
210–230 g were kept for overnight fasting with free access to water. 
The animals were divided into two groups (six animals per group), 
optimized DST-SLN formulation for one group and another one with 
DST-SUS was administered by oral route [11].
Oral administration
Two groups of rats were administered with their respective 
formulations using oral feeding needle based on body weight 10 mg/kg. 
For comparison, Dasatinib suspension was administered to the second 
group. Rats were anesthetized and blood samples (0.5 ml) were collected 
from the retro-orbital venous puncture at 0.5, 1, 2, 4, 6, 8, 10, 12, and 
24 h after drug administration. The blood samples were centrifuged 
(5000 rpm, 15 min) and serum was collected and stored at −20°C until 
high-performance liquid chromatography (HPLC) analysis [12].
Serum drug analysis by HPLC
For  the  determination  of  Dasatinib  in  100  μl  of  serum,  add  25  μl  of 
methanol  and  25  μl  of  internal  standard  (Imatinib,  1  µg/ml)  was 
added and vortexed for 2 min. The samples were made alkaline by 
the  addition  of  100  μl  of  1N  NaOH  and  vortexed  for  3  min.  To  this 
sample, 750 μl of dichloromethane was added and vortexed for 5 min 
and then centrifuged at 4000 rpm for 15 min. The organic layer was 
separated and evaporated. The residue was reconstituted with mobile 
phase  and  a  volume  of  20  μl  of  sample  was  injected  into  HPLC  (LC 
10AT, Shimadzu, Japan) with ultraviolet detector at 321 nm (SPD 10A, 
Shimadzu, Japan) using Lichrospher C18 (250 mm × 4.6 mm, i. e., 5 µm 
particle size) analytical column for the analysis. Acetonitrile:water at a 
ratio 66:34 v/v was used as mobile phase with a flow rate of 1 ml/min. 
Retention time was 10.9 min for DS and 7.2 min for internal standard. 
The standard graph was plotted in the linearity range of 0.1–10 µg/ml 
concentration with r2>0.995 [13].
Calculation of PK parameters and statistical significance
PK parameters such as Cmax, Tmax, area under the curve (AUC), t1/2, and 
mean residence time (MRT) were calculated using Kinetica software 
(version 5.0). The statistical significance of observed differences in 
Cmax, AUC, t1/2, and MRT of different groups was assessed by ANOVA test 
using GraphPad Prism software. All the data were expressed as mean 
±SD. p <0.05 was considered to be statistically significant [14,15].
RESULTS AND DISCUSSION
In vitro cytotoxicity studies
MTT assay method was used for the determination of cytotoxicity of 
DST-SLNs in ATCC cell lines. In this method, the yellow tetrazolium 
salt was reduced by dehydrogenase enzymes present in mitochondria 
of metabolically active cells, to generate reducing equivalents, NADH, 
and NADPH. The formazan product has low aqueous solubility and was 
observable as purple crystals. The resulting formazan was dissolved 
using suitable detergent, permitted the convenient quantification 
of product formation. The intensity of the color of the product was 
measured at 321 nm. From the results, the in vitro cytotoxicity of 
DST-SLN and DST-SUS was dose dependent up to the concentration of 
Fig. 1: In vitro cytotoxicity profiles of Dasatinib (DST)-Solid 
lipid nanoparticle and DST-Suspension in ATCC cell lines 
(mean±standard deviation, n=3)
Fig. 2: Mean serum concentration-time profiles of Dasatinib (DST) 
from DST-Solid lipid nanoparticles and DST-Suspension in rats 
(Mean±standard deviation, n=6)
Table 1: Serum concentrations of DST-SLN in rats
Time (h) Serum levels of DST (µg/mL)
R1 R2 R3 R4 R5 R6
0.5 0.09 0.11 0.24 0.13 0.13 0.1
1 0.26 0.38 0.604 0.53 0.47 0.23
2 0.82 1.1 1.62 1.12 0.88 0.51
4 2.06 1.16 1.66 1.33 1.28 2.05
6 0.91 1.02 0.86 0.79 0.91 1.31
8 0.85 0.71 0.68 0.52 0.71 0.87
10 0.48 0.33 0.29 0.23 0.43 0.21
12 0.03 0.04 0.06 0.04 0.05 0.04
24 0.01 0.02 0.01 0.01 0.03 0.01
DST: Dasatinib, SLN: Solid lipid nanoparticles
10–100 µg/mL. The percentage inhibition was more (89%) with SLN 
formulation when compared to SUS (42%) (Fig.1).
In vivo-bioavailability studies
Oral bioavailability studies of DST-SLN and DST-SUS formulation 
were conducted in male albino Wistar rats. The serum concentration 
levels of DST-SLN and DST-SUS are represented in Tables 1-3. The PK 
parameters were calculated using Kinetica software and the profiles 
are represented in Tables 4-6 and Fig. 2. From the results, the peak 
plasma concentration and peak time concentration were doubled 
compared with DST-SUS formulation. This is the indication of 
prolonged DST levels in the serum. Further, the MRT of DST-SLN was 
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Table 6: PK parameters of DST from DST-SLN and DST-SUS in 
rats (Mean±standard deviation, n=6)
Parameter DST-SLN DST-SUS
Mean±SD Mean±SD
C-max (µg/mL) 1.59±0.39 0.98±0.14
t-max (h) 4.00±0.00 2.00±0.00
AUC total (µg/ml) h 9.31±0.86 4.07±0.52
t1/2 (h) 3.55±0.45 3.27±0.36
MRT (h) 5.70±0.47 4.40±0.30
DST: Dasatinib, SLN: Solid lipid nanoparticles, SUS: Suspension, 
MRT: Mean residence time, AUC: Area under the curve
Table 2: Serum concentrations of Dasatinib-suspension in rats
Time (h) Serum levels of DST (µg/mL)
R1 R2 R3 R4 R5 R6
0.5 0.09 0.08 0.17 0.12 0.14 0.11
1 0.76 0.65 0.81 0.69 0.73 0.65
2 1.01 1.21 0.85 0.91 0.83 1.06
4 0.38 0.42 0.35 0.47 0.38 0.51
6 0.28 0.33 0.21 0.29 0.2 0.4
8 0.18 0.26 0.18 0.14 0.13 0.26
10 0.1 0.08 0.12 0.09 0.05 0.14
12 0.02 0.02 0.01 0.02 0.015 0.02
24 0.007 0.005 0.007 0.006 0.001 0.005
DST: Dasatinib, DST-SUS: Dasatinib-suspension 
Table 4: PK parameters of DST-SLN in rats
Parameter R1 R2 R3 R4 R5 R6
C-max (µg/ml) 2.06 1.16 1.66 1.336 1.288 2.05
t-max (h) 4 4 4 4 4 4
AUC total (µg/ml) h 10 8.75 10.21 8.06 8.91 9.94
t1/2 (h) 3.39 3.83 3.08 3.19 4.29 3.52
MRT (h) 5.72 5.91 5.14 5.25 6.42 5.78
DST: Dasatinib, SLN: Solid lipid nanoparticles, MRT: Mean residence time,  
AUC: Area under the curve, PK: Pharmacokinetic 
Table 5: PK parameters of DST-SUS in rats
Parameter R1 R2 R3 R4 R5 R6
C-max (µg/ml) 1.01 1.21 0.854 0.91 0.83 1.06
t-max (h) 2 2 2 2 2 2
AUC total (µg/ml) h 4.06 4.5 3.69 4 3.36 4.79
t1/2 (h) 3.36 3.43 3.42 3.47 2.53 3.38
MRT (h) 4.57 4.48 4.37 4.47 3.83 4.7
DST: Dasatinib, SUS: Suspension, MRT: Mean residence time AUC: Area under 
the curve, PK: Pharmacokinetic 
Table 3: Mean serum concentration-time profiles of DST-SLN 
and DST-SUS in rats












DST: Dasatinib, SLN: Solid lipid nanoparticles, DS-Dasatinib, SUS: Suspension, 
SD: Standard deviation
almost more compared with DST-SUS, confirmed the increased residence time 
and it is responsible for sustained release behavior from the in vitro 
release studies also.
CONCLUSION
DST is a Biopharmaceutics Classification System Class II drug having 
very low solubility and high permeability. Low aqueous solubility 
and poor dissolution of DST lead to poor bioavailability, Thus, limited 
aqueous solubility is the bottleneck for the therapeutic outcome of 
DST. Animal data suggest that the absolute bioavailability of DST is 
about 14–34% due to an extensive first-pass effect. In the in vitro 
cytotoxicity study, the percentage inhibition was more with DST-
SLN formulation when compared to DST-SUS. The indication of the 
enhanced oral bioavailability is evidenced from the AUC of the test and 
control formulation. DST-SLN and DST-SUS shows the AUCtotal levels at 
9.31±0.86 (μg/ml) h and 4.07±0.52 (μg/ml) h,  respectively. From the 
AUC parameter, about 2.28-fold enhancement in the BA was observed 
in DST-SLN compared with DST-SUS, which is statistically significant at 
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